Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of action

CD73 (ecto-5′-nucleotidase) has recently been established as a promising immuno-oncology target. Given its role in activating purinergic signaling pathways to elicit immune suppression, antagonizing CD73 (i.e., releasing the brake) offers a complimentary pathway to inducing anti-tumor immune respons...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:MAbs
Main Authors: Geoghegan, James C., Diedrich, Gundo, Lu, Xiaojun, Rosenthal, Kim, Sachsenmeier, Kris F., Wu, Herren, Dall'Acqua, William F., Damschroder, Melissa M.
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2016
Assuntos:
Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5037986/
https://ncbi.nlm.nih.gov/pubmed/26854859
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2016.1143182
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados